|

Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)

RECRUITINGPhase 4Sponsored by Region Skane
Actively Recruiting
PhasePhase 4
SponsorRegion Skane
Started2026-09-28
Est. completion2029-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

This is a prospective multicentre randomised controlled trial evaluating whether intraoperative indocyanine green (ICG) fluorescence angiography improves outcomes in head and neck free flap reconstruction compared with standard clinical assessment of flap perfusion. Adult patients undergoing microvascular free flap reconstruction for oncologic, trauma, or benign head and neck defects will be randomised to either intraoperative ICG angiography or conventional clinical perfusion assessment. The primary outcome is partial flap loss requiring intervention within 30 days after surgery. Secondary outcomes include total flap loss, flap-related re-exploration, flap salvage, and postoperative complications.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥18 years at the time of inclusion
* Scheduled to undergo microvascular free flap reconstruction as part of oncologic, trauma, or benign surgery in the head and neck area
* Ability to understand study information and provide written informed consent

Exclusion Criteria:

* Known allergy to indocyanine green or iodine
* Severe hepatic or renal impairment
* Confirmed or suspected pregnancy
* Breastfeeding

Conditions9

CancerFree FlapFree Flap EvaluationFree Tissue FlapsHead and Neck Cancer (H&N)Indocyanine GreenIndocyanine Green (ICG)MicrosurgeryRandomised Controlled Trial

Interventions1

Related trials

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.